Director Appointment

RNS Number : 2910D
Advanced Oncotherapy PLC
26 April 2013
 

26  April 2013

 

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

 

Director Appointment

 

Further to the Issue of Equity announcement released on 24 April 2013, Advanced Oncotherapy is pleased to announce the appointment of Michael Bradfield as a Non-Executive director of the Company. This appointment follows Mr Bradfield's £1m investment in the Company ("the Placing").

 

Michael Bradfield, aged 61, has over 30 years experience of Direct Marketing and the Insurance Industry as founder and CEO of Hospital Plan Insurance Services (HPIS), a direct seller of low cost Health, Accident and Life Insurance. Michael has a law degree from LSE, was the youngest full Member of Lloyds of London and a computer application programmer since the late 1960's, specialising in insurance based administration and correspondence systems and database marketing. HPIS was sold to AIG in 2000 when it expanded into Europe. Since 2004 he has been an active investment manager, especially in technology based companies and sustainable industries.

 

Current Directorships

Past Directorships

Stockgain Asset Management

The Heriot Property Partnership LLP

Henstridge Properties Limited

Twizzle Yachts Limited Liability Partnership

The Vail Foundation

Data For Marketing Limited

Hamilton Capital Management Limited

Acacia Trust

Fairford Capital Limited

Acacia Asset Management Limited


Acacia Research Limited

 

There is no further information required to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

Following the admission of the Placing shares, Mr. Bradfield will hold 100,000,000 ordinary shares, representing approximately 27.8 per cent. of the issued share capital of Advanced Oncotherapy.    

 

Commenting on the appointment, Michael Sinclair, Chief Executive said "I am delighted to welcome Michael to our board. His experience will undoubtedly help us to grow the company and he has already demonstrated his enthusiasm through the substantial investment he has made in Advanced Oncotherapy."

 

For further information, please visit www.advancedoncotherapy.comor contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson

Advanced

Oncotherapy Plc

Libertas Capital

Corporate Finance Ltd

Peterhouse

Corporate Finance

Tavistock Communications


(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

+44 20 3617 8739

+44 20 7569 9650

+44 20 7469 0930

+44 20 7920 3150

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAIAMRTMBITBAJ
UK 100

Latest directors dealings